Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Reports Positive Phase III Results For Mozobil In Stem Cell Transplant

This article was originally published in The Pink Sheet Daily

Executive Summary

NDA filing for patients undergoing hematopoietic stem cell transplant for NHL is anticipated in first half of 2008.

You may also be interested in...



Genzyme Reports More Good News For Mozobil

Second Phase III trial shows twice the stem cell mobilization power called for in multiple myeloma protocol, adding to high efficacy shown in lymphoma study reported in July.

Genzyme Reports More Good News For Mozobil

Second Phase III trial shows twice the stem cell mobilization power called for in multiple myeloma protocol, adding to high efficacy shown in lymphoma study reported in July.

Genzyme’s Tolevamer Misses Endpoint In First Of Two Phase III Studies

“We don’t believe tolevamer will be commercialized in the near future,” Genzyme tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

OM014079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel